These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7629253)

  • 21. Marked reduction of striatal dopamine D2 receptors as detected by 123IBZM-SPECT in a Wilson's disease patient with generalized dystonia.
    Schwarz J; Tatsch K; Vogl T; Kirsch CM; Trenkwalder C; Arnold G; Gasser T; Oertel WH
    Mov Disord; 1992; 7(1):58-61. PubMed ID: 1532631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitory effects of the dopamine agonists quinagolide (CV 205-502) and bromocriptine on prolactin secretion and growth of SMtTW pituitary tumors in the rat.
    Trouillas J; Chevallier P; Claustrat B; Hooghe-Peters E; Dubray C; Rousset B; Girod C
    Endocrinology; 1994 Jan; 134(1):401-10. PubMed ID: 7903933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid re-expansion of a macroprolactinoma after early discontinuation of bromocriptine.
    Orrego JJ; Chandler WF; Barkan AL
    Pituitary; 2000 Nov; 3(3):189-92. PubMed ID: 11383485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cerebral SPECT with iodine-123 IBZM in patients with extrapyramidal system disorders: the evaluation of its sensitivity in therapy with dopaminergic drugs].
    Hierholzer J; Castelli L; Cordes M; Schelosky L; Poewe W; Felix R
    Radiol Med; 1996 Mar; 91(3):207-10. PubMed ID: 8628932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Macroprolactinomas with suprasellar extension: effect of bromocriptine withdrawal during one or more pregnancies.
    Ahmed M; al-Dossary E; Woodhouse NJ
    Fertil Steril; 1992 Sep; 58(3):492-7. PubMed ID: 1521641
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in the prolactin serum isoforms secreted by a pituitary adenoma associated with therapy.
    Morán C; Tena G; Fonseca ME; Ochoa R; Bermúdez JA; Zárate A
    Arch Med Res; 1994; 25(1):1-3. PubMed ID: 8019107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
    Colao A; Di Sarno A; Landi ML; Cirillo S; Sarnacchiaro F; Facciolli G; Pivonello R; Cataldi M; Merola B; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3574-9. PubMed ID: 9360509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy of prolactinoma with a T helper 1 activator adjuvant and autoantigens: a case report.
    Hazrati SM; Aghazadeh J; Mohtarami F; Abouzari M; Rashidi A
    Neuroimmunomodulation; 2006; 13(4):205-8. PubMed ID: 17337912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prolactin secretion after surgery or bromocriptine treatment of prolactinoma.
    De Leo V; Petraglia F; Sardelli S; Danero S; Genazzani AR; D'Antona N
    Obstet Gynecol; 1987 Jan; 69(1):99-103. PubMed ID: 3099236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A patient with a prolactinoma associated with an aldosterone producing adrenal adenoma: differences in dopaminergic regulation of PRL and aldosterone secretion.
    Demura R; Naruse M; Isawa M; Onoda N; Naruse K; Yamakado M; Demura H
    Endocrinol Jpn; 1992 Apr; 39(2):169-76. PubMed ID: 1396349
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up.
    Colao A; Loche S; Cappa M; Di Sarno A; Landi ML; Sarnacchiaro F; Facciolli G; Lombardi G
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2777-80. PubMed ID: 9709946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Malignant prolactinoma discovered by D2 receptor imaging.
    Petrossians P; de Herder W; Kwekkeboom D; Lamberigts G; Stevenaert A; Beckers A
    J Clin Endocrinol Metab; 2000 Jan; 85(1):398-401. PubMed ID: 10634416
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
    Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
    Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study.
    Molitch ME; Elton RL; Blackwell RE; Caldwell B; Chang RJ; Jaffe R; Joplin G; Robbins RJ; Tyson J; Thorner MO
    J Clin Endocrinol Metab; 1985 Apr; 60(4):698-705. PubMed ID: 3882737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low doses of dopamine agonists in the long-term treatment of macroprolactinomas.
    Liuzzi A; Dallabonzana D; Oppizzi G; Verde GG; Cozzi R; Chiodini P; Luccarelli G
    N Engl J Med; 1985 Sep; 313(11):656-9. PubMed ID: 4022058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cerebrospinal fluid rhinorrhea occurring in long-term bromocriptine treatment for macroprolactinomas.
    Bronstein MD; Musolino NR; Benabou S; Marino R
    Surg Neurol; 1989 Nov; 32(5):346-9. PubMed ID: 2814786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo characterisation of 3-iodo-6-methoxybenzamide 123I in humans.
    Costa DC; Verhoeff NP; Cullum ID; Ell PJ; Syed GM; Barrett J; Palazidou E; Toone B; Van Royen E; Bobeldijk M
    Eur J Nucl Med; 1990; 16(11):813-6. PubMed ID: 2209650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-lasting suppression of prolactin secretion and rapid shrinkage of prolactinomas after a long-acting, injectable form of bromocriptine.
    Montini M; Pagani G; Gianola D; Pagani MD; Salmoiraghi M; Ferrari L; Lancranjan I
    J Clin Endocrinol Metab; 1986 Jul; 63(1):266-8. PubMed ID: 3711262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amphetamine-stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates.
    Innis RB; Malison RT; al-Tikriti M; Hoffer PB; Sybirska EH; Seibyl JP; Zoghbi SS; Baldwin RM; Laruelle M; Smith EO
    Synapse; 1992 Mar; 10(3):177-84. PubMed ID: 1532675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Occurrence of extensive spherical amyloid deposits in a prolactin-secreting pituitary macroadenoma: a radiologic-pathologic correlation.
    Levine SN; Ishaq S; Nanda A; Wilson JD; Gonzalez-Toledo E
    Ann Diagn Pathol; 2013 Aug; 17(4):361-6. PubMed ID: 23602507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.